Quotes 5-day view Delayed Nasdaq
01/15/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
24.48(c)
24.96(c)
25.4(c)
24.17(c)
24.05(c)
Last
1 265 058
1 423 363
1 389 863
1 488 238
817 811
Volume
-8.35% +1.96% +1.76% -4.84% -0.50% Change
Sales 2020
22,6 M - -
Net income 2020
-95,7 M - -
Net cash position 2020
260 M - -
P/E ratio 2020
-21,8x
Yield 2020
-
Sales 2021
22,9 M - -
Net income 2021
-123 M - -
Net cash position 2021
92,7 M - -
P/E ratio 2021
-17,3x
Yield 2021
-
Capitalization
2 195 M 2 195 M -
EV / Sales 2020
85,6x
EV / Sales 2021
91,8x
Nbr of Employees
108
Free-Float
90,7%
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics...
Notations Surperformance© of Seres Therapeutics, Inc.
Trading Rating : Investor Rating :
All news about SERES THERAPEUTICS, INC.
News in other languages on SERES THERAPEUTICS, INC.
Analyst Recommendations on SERES THERAPEUTICS, INC.
SERES THERAPEUTICS, INC. - 2020
Close to new upside potential
BUY
Chart SERES THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SERES THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
9
Average target price
37,50 $
Last Close Price
24,05 $
Spread / Highest target
104%
Spread / Average Target
55,9%
Spread / Lowest Target
-0,21%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
